Head-to-head comparisons of medication uses, side effects, warnings, and more.
Inpefa (sotagliflozin)
Farxiga (dapagliflozin)
Inpefa (sotagliflozin)
Farxiga (dapagliflozin)
Summary of Inpefa vs. Farxiga
Summary for SGLT1/SGLT2 inhibitor
Prescription only
Inpefa (sotagliflozin) is a newer medication that's approved to lessen the risk of heart-related complications in people with heart failure and in people with Type 2 diabetes, chronic kidney disease (CKD), and other heart-related conditions. This medication comes as a tablet that you take by mouth once daily. Side effects can include urinary tract infections (UTIs) and diarrhea. Inpefa (sotagliflozin) is expected to be available in the U.S. in summer 2023.
Summary for SGLT2 inhibitor
Prescription only
Farxiga, the brand name for dapagliflozin, is used together with a nutritious diet and exercise plan to lower blood sugar levels in people 10 years and older with Type 2 diabetes. It can also help lower the risk of serious complications, hospitalization, and death in certain adults with heart failure or chronic kidney disease (CKD). Farxiga (dapagliflozin) belongs to the drug class called sodium-glucose cotransporter 2 (SGLT2) inhibitors. It's taken by mouth once a day. Some side effects include yeast infections, urinating more often, and weight loss.
Indications of Inpefa vs. Farxiga
Indications for
•Lessen the risk of heart-related death and complications in adults with:
•Type 2 diabetes (in addition to diet and exercise) in people age 10 and over
•Lowering the risk of hospitalization for heart failure in adults with Type 2 diabetes and heart disease
•Lowering the risk of hospitalization and death due to heart problems in people with heart failure
•Lowering the risk of worsening kidney problems, hospitalization for heart failure, and death due to heart problems in adults with chronic kidney disease (CKD)
Pros and Cons of Inpefa vs. Farxiga
Pros and Const for SGLT1/SGLT2 inhibitor
Pros
•Taken just once a day
•Can lower the risk of heart-related death, heart failure (HF) hospitalizations, and urgent HF visits by up to 33%